Schilling, Marcel; Maiwald, Thomas; Hengl, Stefan; Winter, Dominic; Kreutz, Clemens; Kolch, Walter; Lehmann, Wolf D; Timmer, Jens; Klingmüller, Ursula (2012): Proliferation of retrovirally transduced CFU-E cells after incubation with increasing Epo-concentration (Figure 5c). PANGAEA, https://doi.org/10.1594/PANGAEA.775548
Always quote above citation when using data! You can download the citation in several formats below.
Data contain source data for Figure 5c from Schilling et al., 2009. Cell fate decisions are regulated by the coordinated activation of signalling pathways such as the extracellular signal-regulated kinase (ERK) cascade, but contributions of individual kinase isoforms are mostly unknown. The authors combined quantitative data from erythropoietin-induced pathway activation in primary erythroid progenitor (colony-forming unit erythroid stage, CFU-E) cells with mathematical modelling, in order to predict and experimentally confirmed a distributive ERK phosphorylation mechanism in CFU-E cells. The authors found evidences that double-phosphorylated ERK1 attenuates proliferation beyond a certain activation level, whereas activated ERK2 enhances proliferation with saturation kinetics. Retrovirally transduced CFU-E cells were incubated with increasing Epo concentrations for 14 h and proliferation was measured by [3H]-thymidine incorporation.
Schilling, Marcel; Maiwald, Thomas; Hengl, Stefan; Winter, Dominic; Kreutz, Clemens; Kolch, Walter; Lehmann, Wolf D; Timmer, Jens; Klingmüller, Ursula (2009): Theoretical and experimental analysis links isoformspecific ERK signalling to cell fate decisions. Molecular Systems Biology, 5, https://doi.org/10.1038/msb.2009.91
Date/Time Start: 2007-11-26T00:00:00 * Date/Time End: 2007-11-26T00:00:00
Experiment_ppERK_Treatment_a * Date/Time: 2007-11-26T00:00:00 * Comment: TREATMENT: ERK1=control; ERK2=control; ARK=control
Experiment_ppERK_Treatment_b * Date/Time: 2007-11-26T00:00:00 * Comment: TREATMENT: ERK1=elevated; ERK2=control; ARK=control
|#||Name||Short Name||Unit||Principal Investigator||Method||Comment|
|2||Treatment: chemical concentration (biological activity), of Erythropoietin||T:Epo||U/ml||Schilling, Marcel||Chemical used as treatment; [UniProtKB: P29676] (http://identifiers.org/uniprot/P29676)|
|3||Treatment: Amount concentration, of Extracellular signal-Regulated Kinase 1||T:ERK1||Schilling, Marcel||Chemical used as treatment i.e. elevated or control|
|4||Treatment: Amount concentration, of Extracellular signal-Regulated Kinase 2||T:ERK2||Schilling, Marcel||Chemical used as treatment i.e. elevated or control|
|5||Treatment: Amount concentration, protein kinase B||T:AKT||Schilling, Marcel||Chemical used as treatment i.e. elevated or control|
|6||Detector raw counts||Counts||cpm||Schilling, Marcel||Thymidine incorporation|
800 data points